Roses Allen D
Genetics Research, GlaxoSmithKline, Research Triangle Park, NC 27709, USA.
Life Sci. 2002 Feb 15;70(13):1471-80. doi: 10.1016/s0024-3205(01)01532-6.
Pharmacogenetic evidence-based treatment strategies will have major implications for all aspects of the product pipeline, including drug discovery, high throughput target screening protocols, lead optimization, and drug formulation to produce series of medicines for a particular disease which will meet the efficacy needs of the majority of patients. The initial proof of principle experiments involves whole genome screening for DNA variants and determination of specific patterns of variants associated with adverse events of marketed products [SNP Print(sm)]. Pharmacogenetics has the potential of changing the pipeline model of drug discovery, clinical development, and mass customization marketing.
基于药物遗传学证据的治疗策略将对产品研发的各个方面产生重大影响，包括药物发现、高通量靶点筛选方案、先导化合物优化以及药物制剂，以生产针对特定疾病的一系列药物，满足大多数患者的疗效需求。最初的原理验证实验包括对DNA变异进行全基因组筛选，以及确定与上市产品不良事件相关的特定变异模式[SNP Print(sm)]。药物遗传学有潜力改变药物发现、临床开发和大规模定制营销的研发模式。
